[Immunohistochemical study of the predictive value of oncoproteins p53, HER-2 and c-myc during radiotherapy for squamous cell carcinoma of the cervix]

Authors: Gasparian, NA  Pozharisskii, KM  Zharinov, GM  Vinokurov, VL  Kuznetsova, ME  Neklasova, NIU 
Citation: Gasparian NA, etal., Vopr Onkol. 2007;53(4):439-44.
Pubmed: (View Article at PubMed) PMID:17969407

Out of 80 patients with squamous cell cervical carcinoma (stage II-III), p53 expression was observed in 30% of tumors prior to treatment and 49% in the course of radiotherapy. A correlation between degree of p53 expression before treatment, on the one hand, and overall and recurrence-free survival, on the other, was identified: high expression of mutated gene-suppressor p53 was 53% while for absence or low expression, it rose to 67% (p=0.03). For overexpression, 20-month survival was 65%; absence--81% (p=0.01). Hence, p53 expression may be used as a predictive factor in radiotherapy for cervical carcinoma. No correlation was found between p53 expression, on the one hand, and such basal clinico-morphological parameters as stage, morphological pattern and tumor cell differentiation, on the other. HER2(3t) overexpression occurred in 2 (2.5%) which seems to point to its insignificant role in squamous cell cervical carcinoma. There was no relationship between c-myc expression and long-term results.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 2298526
Created: 2008-07-08
Species: All species
Last Modified: 2008-07-08
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.